Project
A multicenter, randomized, double-blind, parallel-group,placebo-controlled variable treatment duration studyevaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosisfollowed by extended treatment with open-label BAF312
Automatically Closed · 2016 until 2020
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Status
Automatically Closed
Start Date
2016
End Date
2020
Financing
Industry
Study Design
open label
Brief description/objective
Extensionsstudie, Evaluation Sicherheit und Wirksamkeit von Siponimod bei sekundär progredienter MS.